Close Menu

NEW YORK — Vela Diagnostics said on Monday that an automated version of its ViroKey SARS-CoV-2 RT-PCR Test has received CE-IVD marking, as well as provisional authorization from Singapore's Health Sciences Authority.

The test probe-based detects SARS-CoV-2 by targeting conserved regions of the SARS-CoV-2 ORF1a and N genes. It runs on the Singapore-based company's Sentosa SX101 instrument, in conjunction with its Sentosa SA201 instrument or Thermo Fisher Scientific's ABI 7500 Fast Dx and can perform up to 48 tests on a single run.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
12
Sponsored by
Truvian

Antibody testing is expected to play an important role in the management of the COVID-19 pandemic. 

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.